THRD241220C7500
- 0.00
- 0.000.00%
Third Harmonic Bio Newsroom
We're Not Very Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Rate
Morgan Stanley Maintains Third Harmonic Bio(THRD.US) With Buy Rating, Maintains Target Price $20
Analysts Are Bullish on Top Healthcare Stocks: Third Harmonic Bio, Inc. (THRD), Collegium Pharmaceutical (COLL)
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
TD Cowen Maintains Third Harmonic Bio(THRD.US) With Buy Rating
TD Cowen Remains a Buy on Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio | 8-K: Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Press Release: Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Express News | Third Harmonic Bio Q3 Net Income USD -13.8 Million
Express News | Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Third Harmonic Bio | 10-Q: Q3 2024 Earnings Report
12 Health Care Stocks Moving In Monday's Intraday Session
Third Harmonic Bio(THRD.US) Insider Sells US$14.3 Million in Common Stock
Third Harmonic Bio Executive Sells Shares Worth Over $71,000
Third Harmonic Bio Executive Sells Over $140k in Stock
Third Harmonic Bio (NASDAQ:THRD) Is In A Strong Position To Grow Its Business
Third Harmonic Bio to Participate in Upcoming Investor Conferences
Express News | Third Harmonic Shares Are Trading Higher on Continued Strength After the Company Reported Q2 Financial Results Yesterday. Also, Morgan Stanley Upgraded the Stock From Equal-Weight to Overweight and Raised Its Price Target From $12 to $20
Express News | Third Harmonic Bio Inc : Morgan Stanley Raises to Overweight
Express News | Third Harmonic Bio Inc : Morgan Stanley Raises Target Price to $20.00 From $12.00